SinoMab BioScience Limited has published its Interim Report 2026 in both English and Chinese on the HKExnews website and on the company’s own site. Printed copies are available free of charge upon request via email (message@sinomab.com) or through Computershare Hong Kong Investor Services Limited.

Concurrently, the company confirmed its transition to a fully electronic dissemination model for all future corporate communications in line with the Hong Kong Stock Exchange’s revised Listing Rule 2.07A, effective 31 December 2023. These communications cover directors’ reports, annual and interim results (and any summaries), notices of meeting, listing documents, circulars, and proxy forms.

Non-registered shareholders who prefer email delivery must submit functional email addresses through their respective banks, brokers, custodians, nominees, or HKSCC Nominees. Without a registered email, these investors will not receive publication alerts and must monitor the HKExnews and SinoMab websites for updates.

Stakeholders wishing to continue receiving printed materials—either routinely or for specific actionable documents—should complete and return the reply form provided or send a scanned copy by email. Additional inquiries can be directed to the company at +852 3426 9833 during Hong Kong business hours.